<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03247413</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00113297</org_study_id>
    <nct_id>NCT03247413</nct_id>
  </id_info>
  <brief_title>Post-lesion Administration of Dexamethasone to Prevent the Development of Neuritis After Radiofrequency Ablation</brief_title>
  <official_title>Post-lesion Administration of Dexamethasone to Prevent the Development of Neuritis After Radiofrequency Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic neck and back pain has become one of the leading causes of disability and loss of
      productivity. For many patients with facet or sacroiliac joint mediated pain who have
      responded to diagnostic nerve blocks, radiofrequency ablation of the nerves innervating the
      joints can provide long term relief. Radiofrequency ablation (RFA) is a relatively safe
      procedure with minimal risk of adverse events. However, with any procedure involving damage
      to the peripheral nervous system, there is risk of post-procedure neuropathic pain. The
      investigators will test the hypothesis that dexamethasone injection delivered at the time of
      lesion effectively prevents the development of post-ablation neuritis through a
      placebo-controlled, double-blind, randomized trial in patients undergoing cervical, thoracic,
      lumbar, and sacroiliac joint radiofrequency denervations
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Each patient serves as his or her own control. Investigators are recruiting patients who are undergoing bilateral procedures. Each patient will receive dexamethasone at each lesion site post-ablation on one side, and placebo (saline) on the other.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The patient, care providers, and principle investigator will be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of post-ablation neuritis</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">366</enrollment>
  <condition>Neuritis</condition>
  <condition>Radiofrequency Ablation</condition>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lesions where dexamethasone 4 milligram is administered post-radiofrequency ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lesions where 1 milliliter of normal saline is administered post-radiofrequency ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 4 mg/ml</intervention_name>
    <description>dexamethasone 4 milligram given post-ablation at each lesion site</description>
    <arm_group_label>Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Placebo, normal saline administered post-ablation at each lesion site</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with a diagnosis of either cervical, thoracic, or lumbar facet or sacroiliac
             joint pain who have responded to medial branch blocks and are already scheduled for
             bilateral radiofrequency ablations

          -  age greater than 18 years old

          -  English speaking

        Exclusion Criteria:

          -  patient not previously scheduled for radiofrequency ablation of the cervical,
             thoracic, or lumbar facets, or sacroiliac joints

          -  on anticoagulation

          -  have a pacemaker

          -  age less than 18 years old

          -  non-English speaking
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Akhil Chhatre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Akhil Chhatre, MD</last_name>
    <phone>(410) 614-4030</phone>
    <email>achhatr1@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Teresa Tang, MD</last_name>
    <phone>(410) 502-2447</phone>
    <email>ttang11@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akhil Chhatre, MD</last_name>
      <phone>410-614-4030</phone>
      <email>achhatr1@jhmi.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2017</study_first_submitted>
  <study_first_submitted_qc>August 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2017</study_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

